Startups
CranioSense is a clinical stage startup on a mission to unlock the hidden parameters of brain health by enabling on demand neurological insight and treatment across the neurological care spectrum. IPASS (Intracranial Pressure Assessment and Screening System) is the first product that we are bringing to the market to realize that mission, a noninvasive medical device for initial diagnosis and continuous monitoring of intracranial hypertension, the point at which ICP becomes clinically unacceptable. CranioSense is a subsidiary of Vivonics
Overview
Location
United States, Massachusetts, Bedford
Employees
1-10
Founded date
2022
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 18, 2025 | CranioSense Receives $5.5M in Federal Grants | CranioSense, Inc., a Bedford, MA-based neurotechnology company developing a noninvasive intracranial pressure (ICP) diagnostic and monitoring system, received an award of approximately $5.5m in total non-dilutive funding through the NIH Blu... |
| Dec 18, 2025 | Arcads.ai Raises USD16M in Seed Funding | Arcads.ai, a San Francisco, CA-based provider of a go-to platform for creating marketing videos with AI, raised $16m in Seed funding. The round was led by Eurazeo, with participation from Alpha Intelligence Capital and other international i... |
Reviews 0
FAQ about CranioSense
When was CranioSense founded?
CranioSense was founded in 2022.
What has the press written about CranioSense?
Parsers VC has collected 3 articles mentioning CranioSense, among them “CranioSense Receives $5.5M in Federal Grants” (Dec 18, 2025) and “Arcads.ai Raises USD16M in Seed Funding” (Dec 18, 2025).
Is CranioSense still active?
Yes, CranioSense is active; its latest activity on Parsers VC dates from Dec 20, 2025.